Email Updates

Search form

You are here

PrEP

Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

The Indian Council of Medical Research (ICMR) has indicated it is planning to study the effectiveness of PrEP in high-risk groups. Those high risk groups include MSM and trans women.

November 3, 2018
Gay Star News

In Nigeria, more than 3 million people are living with HIV, but less than 400 people at the highest risk of infection are using PrEP, widely regarded as a key tool in the battle against the disease’s spread.

November 7, 2018
Devex

This post by HIV.gov looks at the potential role of apps in HIV prevention and treatment, particularly for youth. Dr. Lisa Hightow-Weidman, M.D., M.P.H. discusses her work at the N.I.H. funded University of North Carolina/Emory Center for Innovative Technology (iTech) where she is developing an APP aimed at supporting PrEP use among young people at risk of HIV.

November 8, 2018
HIV.gov

Around four in ten women and one in ten men taking injectable cabotegravir as pre-exposure prophylaxis (PrEP) still have evidence of the drug in their body around 18 months after their last injection, Raphael Landovitz of the University of California told the HIV Research for Prevention conference (HIVR4P 2018) in Madrid yesterday. While providing evidence of the durability and potency of injectable cabotegravir, the findings raise concerns about the potential development of drug resistance.

October 25, 2018
aidsmap

At least 309,525 people have started to take PrEP in 68 countries, but 71 percent of PrEP users are in North America, according to a global analysis presented by AVAC to the HIVR4P conference in Madrid. Laura Fitch of AVAC presented the latest data from the Global PrEP Tracker, an ongoing project run by AVAC and the Clinton Health Access Initiative.

October 23, 2018
aidsmap
Subscribe to RSS - PrEP